Ironwood Pharmaceuticals, Inc. (IRWD)’s Stock Insider Trade – Mark Currie Sold 1,634 Shares; Ikonics Has 1 Sentiment

February 23, 2018 - By Dolores Ford

Chief Scientific Officer Mark Currie of Ironwood Pharmaceuticals Inc, unloaded some 1,634 of the public firm shares worth near $23,954 USD with an average of $14.7 stock price for each share. It seems he is very active lately as in the last month, he unloaded additional 60,000 shares of the company, worth $927,000 USD. Mark Currie today has ownership of 775,000 shares which are equivalent to roughly 0.52% of the Massachusetts-based company’s market cap (total dollar market value of all company’s outstanding shares).

IKONICS Corporation develops, manufactures, and sells photosensitive liquids and films for the screen printing, and awards and recognition industries primarily in the United States. The company has market cap of $17.77 million. It operates through five divisions: Domestic, Export, IKONICS Imaging, Digital Texturing Technology, and Advanced Material Solutions. It currently has negative earnings. The firm sells screen printing films, emulsions, and inkjet receptive films to distributors; and photo resistant films, art supplies, glass, metal medium, and related abrasive etching equipment to end user customers.

The stock increased 12.63% or $1.0001 during the last trading session, reaching $8.9201. About 32,836 shares traded or 567.94% up from the average. IKONICS Corporation (IKNX) has declined 21.10% since February 23, 2017 and is downtrending. It has underperformed by 37.80% the S&P500.

Jnba Financial Advisors holds 0.02% of its portfolio in IKONICS Corporation for 10,624 shares. Blackrock Inc. owns 237 shares or 0% of their US portfolio. Moreover, Morgan Stanley has 0% invested in the company for 1,845 shares. The Ontario – Canada-based Royal Bank Of Canada has invested 0% in the stock. Us Bancorp De, a Minnesota-based fund reported 11,842 shares.

Among 15 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Ironwood Pharmaceuticals has $24 highest and $8 lowest target. $16’s average target is 7.89% above currents $14.83 stock price. Ironwood Pharmaceuticals had 37 analyst reports since August 6, 2015 according to SRatingsIntel. Bank of America downgraded the shares of IRWD in report on Friday, January 5 to “Sell” rating. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Hold” rating by J.P. Morgan on Friday, July 21. The company was maintained on Friday, October 6 by Mizuho. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Neutral” rating by Goldman Sachs on Monday, March 21. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Buy” rating by BTIG Research on Friday, December 11. Wedbush maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Monday, October 24 with “Neutral” rating. The stock has “Hold” rating by Mizuho on Tuesday, January 9. The firm earned “Outperform” rating on Wednesday, April 6 by Cowen & Co. On Friday, August 4 the stock rating was maintained by Cowen & Co with “Buy”. The firm has “Buy” rating by Mizuho given on Tuesday, June 6.

Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on May, 14. They expect $-0.15 earnings per share, up 54.55% or $0.18 from last year’s $-0.33 per share. After $-0.14 actual earnings per share reported by Ironwood Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.14% negative EPS growth.

Since September 5, 2017, it had 0 insider purchases, and 3 sales for $983,540 activity. The insider Currie Mark G sold 60,000 shares worth $927,000. McHugh Julie had sold 1,500 shares worth $24,240 on Tuesday, September 5. Shares for $32,300 were sold by OLANOFF LAWRENCE S.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.22 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: